Introduction
Heart failure with reduced ejection fraction (HFrEF) poses a significant clinical challenge, characterized by a state of chronic inflammation and neurohormonal activation. Recent advances in pharmacotherapy, particularly the advent of sodium-glucose cotransporter-2 inhibitors (SGLT2i), have transformed management strategies for HFrEF. Among these benefits are improvements in cardiovascular outcomes. However, there are concerns about potential side effects associated with these agents, particularly regarding hematological changes such as erythrocytosis, which may elevate thromboembolic risk.
